Sofwave Medical Q1 revenue jumps 46% to $24.4M with net income turnaround

Sofwave Medical reported a strong first quarter for fiscal 2026, with revenue rising 46% year-over-year to $24.4 million and net income turning positive at $1.3 million under IFRS. The company saw a 56% increase in recurring usage fees, reflecting growing adoption of its non-invasive aesthetic treatments, especially among patients using GLP-1 therapies. Gross margin remained robust at 75%, and operating expenses as a percentage of revenue decreased, signaling improved efficiency. With nearly 2,900 systems sold and over 865,000 treatments performed, Sofwave is capitalizing on rising demand for regenerative aesthetic solutions and plans to continue expanding its global market presence.